What You Should Know About the Coronavirus Drug Under Study

More on the coronavirus drug debate. Is a 91.7% success rate with hydroxychloroquine and azithromycin — too good to be true? Dr. Kenny Lin, a otolaryngologist, offers a critical review of the latest data.

  • The Great Hydroxychloroquine Debate: A 91.7% success rate with hydroxychloroquine and azithromycin — too good to be true? A critical review of the latest data.

  • Hydroxychloroquine has been shown in the laboratory to be effective against coronaviruses including SARS and COVID-19 by blocking entry of the virus into cells.

  • More on the coronavirus drug debate: Is a 91.7% success rate with hydroxychloroquine and azithromycin — too good to be true? Dr. Kenny Lin, a otolaryngologist, offers a critical review of the latest data.

 

The Study: On Apr. 10, Dr. Raoult posted to his Twitter a pre-publication abstract and data table summarizing his findings in just over 1,000 patients. Below, I will report the relevant findings (in bold) followed by the methodological issues and omissions that need to be answered.

 

 

 

Conclusion: Dr. Raoult’s latest publication appears very promising on first glance — 91.7% cure within 10 days and 0.5% mortality! However, I am concerned about the lack of a control group and the lack of transparency about the patient selection process. An intentional or unintentional selection of a younger and healthier patient cohort may result in excellent outcomes irregardless of hydroxychloroquine. We need the full manuscript to evaluate whether this abstract is indeed promising or misleading. The gold standard remains a double-blind, randomized control trial. I sincerely hope we get data from such trials in the near future.

Source: https://coronavirus.medium.com/what-you-should-know-about-the-coronavirus-drug-under-study-fa2146e735a1

Leave a Reply

Your email address will not be published. Required fields are marked *